Speaker(s): 

Uwaila Omorogbe, PharmD,  Resident, Geisinger - has nothing to disclose 

Moderator(s): 

Sarah Hale, Pharm.D., BCPPS. Director of Pharmacy, Geisinger-has nothing to disclose 

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

• Discuss the mechanism of action of Xanomeline/Trospium​
•  Explain the impact of the Emergent-2 trial​ 
•  Identify the potential role of Xanomeline/Trospium in the treatment of schizophrenia​                                                                                                                                                                         

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Sarah F. Hale, PharmD, Brain Simpkins, PharmD, Jessica Milheim, CPhT, and Tiffany Tang, PharmD have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPAA compliant. 

Commercial Support for this Session

None